Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

SELARL PHARMACIE DE WIGNEHIES : revenue, balance sheet and financial ratios

SELARL PHARMACIE DE WIGNEHIES is a French company founded 13 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in WIGNEHIES (59212), this company of category PME shows in 2024 a net income positive of 80 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - SELARL PHARMACIE DE WIGNEHIES (SIREN 801548934)
Indicator 2024 2023 2022 2021 2020 2019 2018 2017 2016
Revenue N/C N/C N/C N/C N/C N/C N/C N/C N/C
Net income 80 409 € 110 402 € 147 299 € 130 829 € 113 157 € 140 884 € 110 199 € 129 849 € 134 559 €
EBITDA N/C N/C N/C N/C N/C N/C N/C N/C N/C
Net margin N/C N/C N/C N/C N/C N/C N/C N/C N/C

Revenue and income statement

In 2024, SELARL PHARMACIE DE WIGNEHIES generates positive net income of 80 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2024: 135 k€ -> 80 k€.

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

80 409 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 30%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 64%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

30.21%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

63.995%

Solvency indicators evolution
SELARL PHARMACIE DE WIGNEHIES

Sector positioning

Debt ratio
30.21 2024
2022
2023
2024
Q1: 16.46
Med: 58.47
Q3: 154.89
Good -12 pts over 3 years

In 2024, the debt ratio of SELARL PHARMACIE DE WIGNE... (30.21) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.

Financial autonomy
63.99% 2024
2022
2023
2024
Q1: 28.91%
Med: 49.95%
Q3: 69.47%
Good +9 pts over 3 years

In 2024, the financial autonomy of SELARL PHARMACIE DE WIGNE... (64.0%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.

Positioning of SELARL PHARMACIE DE WIGNEHIES in its sector

Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé

Valuation estimate

Based on 225 transactions of similar company sales in 2024, the value of SELARL PHARMACIE DE WIGNEHIES is estimated at 1 122 569 € (range 781 739€ - 1 679 427€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2024
225 transactions
781k€ 1122k€ 1679k€
1 122 569 € Range: 781 739€ - 1 679 427€
NAF 5 année 2024

Valuation method used

Net Income Multiple
80 409 € × 14.0x = 1 122 569 €
Range: 781 739€ - 1 679 428€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare SELARL PHARMACIE DE WIGNEHIES with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de détail de produits pharmaceutiques en magasin spécialisé

Frequently asked questions about SELARL PHARMACIE DE WIGNEHIES

What is the revenue of SELARL PHARMACIE DE WIGNEHIES ?

The revenue of SELARL PHARMACIE DE WIGNEHIES is not publicly disclosed (confidential accounts filed with INPI).

Is SELARL PHARMACIE DE WIGNEHIES profitable?

Yes, SELARL PHARMACIE DE WIGNEHIES generated a net profit of 80 k€ in 2024.

Where is the headquarters of SELARL PHARMACIE DE WIGNEHIES ?

The headquarters of SELARL PHARMACIE DE WIGNEHIES is located in WIGNEHIES (59212), in the department Nord.

Where to find the tax return of SELARL PHARMACIE DE WIGNEHIES ?

The tax return of SELARL PHARMACIE DE WIGNEHIES is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does SELARL PHARMACIE DE WIGNEHIES operate?

SELARL PHARMACIE DE WIGNEHIES operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.